Focal Interest
Focal Interest

Chondrosarcoma

  1. Olutasidenib showed disease control in IDH1-mutated chondrosarcoma
    Phase 1b/2 trial of olutasidenib in IDH1-mutated chondrosarcoma shows disease control without dose-limiting toxicities; 52% stable disease rate in recurrent/metastatic disease.
  2. Combination therapy showed a temporary response in metastatic DDCS
    Case report demonstrates promising response to pembrolizumab and pazopanib combination therapy in metastatic dedifferentiated chondrosarcoma, highlighting emerging systemic treatment options.
  3. Pediatric maxillary mesenchymal chondrosarcoma with HEY1::NCOA2 fusion
    Case report of mesenchymal chondrosarcoma in a 13-year-old with HEY1::NCOA2 fusion treated with multimodal therapy including sirolimus targeting mTOR pathway.
  4. Three biomarkers were linked to angiogenesis and ISR in chondrosarcoma
    Multi-omics analysis identifies HSPA8, LMNA, and SERPINH1 as angiogenesis and integrated stress response biomarkers in chondrosarcoma with therapeutic potential.